




PHARMACEUTICAL 2023

Revance Therapeutics Inc.
Rank 344 of 446

REVANCE®





PHARMACEUTICAL 2023

Revance Therapeutics Inc.
Rank 344 of 446

REVANCE®

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Revance Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is -58%, being 101% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	374,727
Cost of Goods Sold	0
Intangible Assets	104,179
Liabilities, Current	75,682
Liabilities, Non-Current	114,244
Other Assets	80,855
Other Compr. Net Income	-356
Other Expenses	166,477
Other Liabilities	379,374
Other Net Income	2,710
Other Revenues	132,565
Property and Equipment	22,139
Research and Development	101,286
Selling, General and Administrative Expense	223,934

Output Variable	Value in 1000 USD
Assets	581,900
Liabilities	569,300
Expenses	491,697
Revenues	132,565
Stockholders Equity	12,600
Net Income	-356,422
Comprehensive Net Income	-356,600
Economic Capital Ratio	-58%